CY1117379T1 - Παραγωγα ιμιδαζολιου ως αναστολεις toy tafi-a - Google Patents
Παραγωγα ιμιδαζολιου ως αναστολεις toy tafi-aInfo
- Publication number
- CY1117379T1 CY1117379T1 CY20161100053T CY161100053T CY1117379T1 CY 1117379 T1 CY1117379 T1 CY 1117379T1 CY 20161100053 T CY20161100053 T CY 20161100053T CY 161100053 T CY161100053 T CY 161100053T CY 1117379 T1 CY1117379 T1 CY 1117379T1
- Authority
- CY
- Cyprus
- Prior art keywords
- tafi
- toy
- suspensions
- imidazolium derivatives
- compounds
- Prior art date
Links
- 150000004693 imidazolium salts Chemical class 0.000 title 1
- 239000000725 suspension Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010035664 Pneumonia Diseases 0.000 abstract 1
- 108090000190 Thrombin Proteins 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000020764 fibrinolysis Effects 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 230000009610 hypersensitivity Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000009863 secondary prevention Effects 0.000 abstract 1
- 229960004072 thrombin Drugs 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005049385A DE102005049385A1 (de) | 2005-10-15 | 2005-10-15 | Imidazolderivate als Inhibitoren von TAFIa |
| EP06792327.6A EP1937673B1 (de) | 2005-10-15 | 2006-09-30 | Imidazolderivate als inhibitoren von tafi-a |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1117379T1 true CY1117379T1 (el) | 2017-04-26 |
Family
ID=37733974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20161100053T CY1117379T1 (el) | 2005-10-15 | 2016-01-20 | Παραγωγα ιμιδαζολιου ως αναστολεις toy tafi-a |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8044208B2 (https=) |
| EP (1) | EP1937673B1 (https=) |
| JP (1) | JP5266053B2 (https=) |
| CY (1) | CY1117379T1 (https=) |
| DE (1) | DE102005049385A1 (https=) |
| DK (1) | DK1937673T3 (https=) |
| ES (1) | ES2558874T3 (https=) |
| HU (1) | HUE026577T2 (https=) |
| PL (1) | PL1937673T3 (https=) |
| PT (1) | PT1937673E (https=) |
| SI (1) | SI1937673T1 (https=) |
| WO (1) | WO2007045339A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009103432A2 (en) * | 2008-02-21 | 2009-08-27 | Sanofi-Aventis | Covalently binding imaging probes |
| WO2010050525A1 (ja) | 2008-10-29 | 2010-05-06 | 大正製薬株式会社 | ＴＡＦＩａ阻害活性を有する化合物 |
| BR112012023412A2 (pt) | 2010-03-18 | 2018-05-08 | Daiichi Sankyo Company, Limited | composto, drogra farmacêutica, inibidor de tafia, promotor de fibrinólise, droga preventiva ou terapêutica, composição farmacêutica, e, uso de um composto. |
| EP2548871B1 (en) | 2010-03-18 | 2017-07-19 | Daiichi Sankyo Company, Limited | Cycloalkyl-substituted imidazole derivative |
| KR101799429B1 (ko) | 2010-05-03 | 2017-11-21 | 에스케이바이오팜 주식회사 | 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물 |
| US8809372B2 (en) | 2011-09-30 | 2014-08-19 | Asana Biosciences, Llc | Pyridine derivatives |
| US9199975B2 (en) | 2011-09-30 | 2015-12-01 | Asana Biosciences, Llc | Biaryl imidazole derivatives for regulating CYP17 |
| KR20160018557A (ko) | 2013-06-10 | 2016-02-17 | 사노피 | TAFIa의 저해제로서의 마크로사이클릭 우레아 유도체, 이의 제법 및 의약품으로서의 이의 용도 |
| MX2022007376A (es) | 2019-12-20 | 2022-09-02 | Tenaya Therapeutics Inc | Fluoroalqull-oxadiazoles y sus usos. |
| US20240252502A1 (en) | 2021-05-04 | 2024-08-01 | Tenaya Therapeutics, Inc. | Hdac6 inhibitors for treatment of metabolic disease and hfpef |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE447557T1 (de) * | 2000-08-17 | 2009-11-15 | Pfizer Ltd | Substitutuierte imidazole als tafia inhibitoren |
| WO2003013526A1 (en) * | 2001-08-08 | 2003-02-20 | Merck & Co. Inc. | Anticoagulant compounds |
| BR0307033A (pt) * | 2002-01-22 | 2004-12-07 | Pfizer | ácidos 3-(imidazolil)-2-aminopropanóicos para o uso como inibidores tafi-a para o tratamento de doenças trombóticas |
-
2005
- 2005-10-15 DE DE102005049385A patent/DE102005049385A1/de not_active Withdrawn
-
2006
- 2006-09-30 PL PL06792327T patent/PL1937673T3/pl unknown
- 2006-09-30 SI SI200632014T patent/SI1937673T1/sl unknown
- 2006-09-30 HU HUE06792327A patent/HUE026577T2/hu unknown
- 2006-09-30 DK DK06792327.6T patent/DK1937673T3/en active
- 2006-09-30 JP JP2008534894A patent/JP5266053B2/ja not_active Expired - Fee Related
- 2006-09-30 EP EP06792327.6A patent/EP1937673B1/de not_active Not-in-force
- 2006-09-30 ES ES06792327.6T patent/ES2558874T3/es active Active
- 2006-09-30 WO PCT/EP2006/009500 patent/WO2007045339A1/de not_active Ceased
- 2006-09-30 PT PT67923276T patent/PT1937673E/pt unknown
-
2008
- 2008-04-14 US US12/102,105 patent/US8044208B2/en not_active Expired - Fee Related
-
2016
- 2016-01-20 CY CY20161100053T patent/CY1117379T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009511516A (ja) | 2009-03-19 |
| WO2007045339A1 (de) | 2007-04-26 |
| HUE026577T2 (hu) | 2016-06-28 |
| US20080262028A1 (en) | 2008-10-23 |
| JP5266053B2 (ja) | 2013-08-21 |
| EP1937673A1 (de) | 2008-07-02 |
| DK1937673T3 (en) | 2016-01-25 |
| SI1937673T1 (sl) | 2016-02-29 |
| US8044208B2 (en) | 2011-10-25 |
| ES2558874T3 (es) | 2016-02-09 |
| PL1937673T3 (pl) | 2016-03-31 |
| PT1937673E (pt) | 2016-02-08 |
| EP1937673B1 (de) | 2015-10-21 |
| DE102005049385A1 (de) | 2007-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1117379T1 (el) | Παραγωγα ιμιδαζολιου ως αναστολεις toy tafi-a | |
| CY1108087T1 (el) | ΠΑΡΑΓΩΓΑ ΙΜΙΔΑΖΟΛΙΟΥ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΤΟΥ TAFIa | |
| CY1119077T1 (el) | Παραγωγα πυραζολυλαμινοπυριδινης χρησιμα ως αναστολεις κινασων | |
| CY1119281T1 (el) | Καινοφανεις μακροκυκλοι ως αναστολεις τελεστη xiα | |
| EA201100311A1 (ru) | Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы | |
| DK1853602T3 (da) | Kemiske forbindelser | |
| CY1108275T1 (el) | Χημικες ενωσεις | |
| EA200870117A1 (ru) | Азаиндоловые ингибиторы аурора-киназ | |
| EA200802058A1 (ru) | Производные циклоалкиламинокислот и их фармацевтические композиции | |
| CY1117078T1 (el) | Παραγωγα 1-((5-ετεροαρυλθειαζολ-2-υλ) αμινοκαρβονυλ) πυρρολιδινο-2-καρβοξαμιδης ως αναστολεις φωσφατιδυλινοσιτολ 3-κινασης (ρι3κ) χρησιμα στη θεραπεια πολλαπλασιαστικων νοσων | |
| NO20081554L (no) | Isoindollmidforbindelser og sammensetninger omfattende samme, og anvendelse derav | |
| NO20064763L (no) | Forbindelser og fremgangsmater for behandling av dyslipidemi | |
| SE0303180D0 (sv) | Novel compounds | |
| SE0302232D0 (sv) | Novel Compounds | |
| ATE522536T1 (de) | Pyrrolopyrazin-kinasehemmer | |
| CY1113320T1 (el) | Σπειρο-κυκλικα νιτριλια ως αναστολεις πρωτεασης | |
| EA201590284A1 (ru) | Дигидропиридон р1 в качестве ингибиторов фактора xia | |
| ECSP088369A (es) | Novedosos derivados de 1-aza-bicicloalquilo para el tratamiento de trastornos psicóticos y neurodegenerativos | |
| EA200801362A1 (ru) | Пиримидинил бензотиофеновые соединения | |
| EA200801608A1 (ru) | Производные бензимидазолонкарбоновой кислоты | |
| EA202190464A1 (ru) | Замещенные бензимидазолы в качестве ингибиторов pad4 | |
| CY1112520T1 (el) | Βενζυλαμινες, μια διαδικασια για την παραγωγη τους και η χρηση τους ως αντι-φλεγμονωδεις παραγοντες | |
| EA201070779A1 (ru) | Триазолсодержащие производные оксадиазола | |
| ATE517873T1 (de) | 6-oxo-1,6-dihydropyrimidin-2-yle bei der behandlung proliferativer krankheiten | |
| CY1116384T1 (el) | Παραγωγα σουλφαμιδιου ως αναστολεις tafia |